Page last updated: 2024-08-24

topotecan and Peritoneal Neoplasms

topotecan has been researched along with Peritoneal Neoplasms in 49 studies

Research

Studies (49)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.04)	18.2507
2000's	34 (69.39)	29.6817
2010's	13 (26.53)	24.3611
2020's	1 (2.04)	2.80

Authors

Authors	Studies
Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A	1
Atlas, I; Barak, F; Berman, T; Bruchim, I; Levy, T; Meirovitz, M; Rosengarten, OS; Safra, T; Yachnin, A	1
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q	1
Chang Chien, CC; Fu, HC; Hu, CF; Lin, H; Ou, YC; Tsai, CC; Wu, CH	1
Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T	1
Malpass, TW; McGonigle, KF; Muntz, HG; Robertson, MD; Weiden, PL	1
Goff, BA; Holmberg, LA; Kurland, BF; Veljovich, D	1
Coleman, RL; Gibb, RK; Herzog, TJ; Lippmann, L; Mutch, DG; Powell, MA; Rader, JS	1
Fusco, N; Haba, P; Rodriguez, M; Rose, PG; Smrekar, M	1
Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL	1
Balthasar, JP; Bernacki, RJ; Shah, DK; Shin, BS; Tóth, K; Veith, J	1
Ames, MM; Ansell, SM; Barrette, BA; Dispenzieri, A; Elliott, MA; Frost, MH; Gastineau, DA; Gertz, MA; Hartmann, LC; Inwards, DJ; Kaufmann, SH; Keeney, GL; Lacy, MQ; Lingle, WL; Litzow, MR; Long, HJ; Micallef, IN; Peethambaram, PP; Porrata, LF; Reid, JM; Safgren, SL; Suman, VJ	1
Belau, A; Bogenrieder, T; Doering, G; Harter, P; Kurzeder, C; Kuznik, A; Lichtenegger, W; Lorenz, R; Mahner, S; Markmann, S; Meerpohl, HG; Mueller, L; Nugent, A; Oskay-Oezcelik, G; Schroeder, W; Sehouli, J; Sommer, H; Stengel, D; Wilke, J; Wischnik, A	1
DeBernardo, RL; DeGeest, K; Herzog, TJ; Lentz, SS; Mutch, D; O'Malley, D; Shahin, M; Sill, MW; Walker, JL; Weiner, SA	1
Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C	1
Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL	1
Camporeale, A; Cormio, G; De Mitri, P; Gissi, F; Leone, L; Loizzi, V; Putignano, G; Selvaggi, L	1
Goff, BA; Gray, HJ; Greer, BE; Malpass, TW; McGonigle, KF; Muntz, HG; Paley, PJ; Veljovich, DS; Vuky, J	1
Arnold, AG; Grisham, RN; Hyman, DM; Iasonos, A; Kauff, ND; Spriggs, D; Zhou, Q	1
Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C	1
Brown, JV; Drescher, CW; Graham, CL; Micha, JP; Peters, WA; Rettenmaier, MA; Smith, MR	1
Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M	1
Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV	1
Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K	2
Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA	1
Edgerton, CC; Gilman, M; Roth, BJ	1
Buller, RE; Geisler, JP; Lush, R; Sanders, L; Shahin, MS; Sood, AK; Sorosky, JI; Sullivan, D	1
Glezerman, M; Grisaru, D; Inbar, M; Levy, T; Menczer, J; Safra, T	1
Beeler, JF; Haba, P; Rose, PG; Smrekar, M; Visser, C	1
Chen, MD; Fleming, GF; Horowitz, I; Mitchell, S	1
Bell, JG; Fusco, NL; Markman, M; Rose, PG	1
Fan, SM; Feng, YJ; Yao, M; Yi, XF	1
Coleman, RL; Gibb, RK; Gossner, G; Herzog, TJ; Horowitz, NS; Mutch, DG; Powell, MA; Rader, JS	1
Gibb, R; Herzog, TJ; Mutch, DG; Powell, MA; Rader, JS	1
Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM	1
Collado, MV; García Villanueva, A; Pérez de Oteyza, J; Rojo, R; Ruiz-Tovar, J	1
Bernstein, R; Golan, A; Grisaru, D; Inbar, MJ; Levy, T; Menczer, J; Safra, T; Shpigel, S	1
Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E	1
Abushahin, F; Grendys, EC; Lurain, JR; Rademaker, AW; Schink, JC; Singh, DK	1
Chen, TT; Escalon, J; Hills, D; Hochster, H; Ivy, P; Liebes, L; Lu, JM; Muggia, F; Sorich, J	1
Alvarez, RD; Andrews, S; Bryant, C; Heilbrun, LK; Malone, J; Morris, R; Munkarah, A; Schimp, V; Smith, D	1
Ghamande, SA; Piver, MS	1
Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K	1
Brown, JV; Dillman, RA; Drescher, CW; Karlan, BY; Micha, JP; Peters, WA; Rettenmaier, MA; Smith, MR	1
Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J	1
Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D	1
Berkowitz, RS; Campos, SM; Cook, S; Fuller, AF; Goodman, A; MacNeill, KM; Matulonis, UA; Penson, RT; Seiden, MV; Supko, JG	1
Rodriguez, M; Rose, PG	1

Trials

35 trial(s) available for topotecan and Peritoneal Neoplasms

Article	Year
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32 Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult	2020
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:3 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Israel; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan	2013
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult	2014
Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma. Cancer, 2008, Aug-01, Volume: 113, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Female; Humans; Infusions, Parenteral; Middle Aged; Models, Biological; Ovarian Neoplasms; Peritoneal Neoplasms; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome	2008
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. Gynecologic oncology, 2008, Volume: 110, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topotecan	2008
Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecologic oncology, 2008, Volume: 111, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan; Vinblastine; Vinorelbine	2008
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. American journal of clinical oncology, 2008, Volume: 31, Issue:5 Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Prognosis; Survival Rate; Topotecan	2008
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan	2009
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone marrow transplantation, 2010, Volume: 45, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2010
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-10, Volume: 29, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topoisomerase I Inhibitors; Topotecan	2011
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecologic oncology, 2011, Volume: 120, Issue:3 Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Topoisomerase I Inhibitors; Topotecan	2011
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic oncology, 2011, Volume: 122, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan	2011
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer, 2011, Aug-15, Volume: 117, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Topotecan	2011
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecologic oncology, 2011, Volume: 123, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan	2011
Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecologic oncology, 2003, Volume: 88, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Recombinant Proteins; Topotecan	2003
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan	2004
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecologic oncology, 2003, Volume: 91, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2003
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecologic oncology, 2004, Volume: 94, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2004
Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic oncology, 2004, Volume: 95, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan	2004
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1 Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Chromatography, High Pressure Liquid; Disease Progression; DNA; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Recurrence; Time Factors; Topotecan; Treatment Outcome	2004
Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2004
A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecologic oncology, 2005, Volume: 99, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2005
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic oncology, 2006, Volume: 100, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2006
Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. Gynecologic oncology, 2006, Volume: 102, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2006
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecologic oncology, 2006, Volume: 103, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Epithelial Cells; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecologic oncology, 2006, Volume: 103, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2006
Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecologic oncology, 2007, Volume: 105, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Topotecan	2007
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecologic oncology, 2008, Volume: 108, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Topotecan; Treatment Outcome	2008
Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecologic oncology, 2008, Volume: 109, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Survival Rate; Topotecan	2008
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study. Journal of surgical oncology, 1999, Volume: 72, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Salvage Therapy; Topotecan	1999
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecologic oncology, 2000, Volume: 79, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2000
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecologic oncology, 2000, Volume: 79, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Epithelium; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Sleep Stages; Topotecan	2000
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan	2000
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. Gynecologic oncology, 2001, Volume: 81, Issue:2 Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan	2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer, 2001, Sep-01, Volume: 92, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric; Survival Rate; Topotecan	2001

Other Studies

14 other study(ies) available for topotecan and Peritoneal Neoplasms

Article	Year
The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience. Taiwanese journal of obstetrics & gynecology, 2015, Volume: 54, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2015
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecologic oncology, 2015, Volume: 139, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult	2015
Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. The Journal of pharmacology and experimental therapeutics, 2009, Volume: 329, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cisplatin; Computer Simulation; Injections, Intraperitoneal; Injections, Subcutaneous; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Peritoneal Neoplasms; Tissue Distribution; Topotecan; Vascular Endothelial Growth Factor A	2009
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecologic oncology, 2011, Volume: 122, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan	2011
Long-term topotecan therapy in recurrent or persistent ovarian cancer. European journal of gynaecological oncology, 2011, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease Progression; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic oncology, 2011, Volume: 123, Issue:2 Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan	2011
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecologic oncology, 2004, Volume: 93, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Topotecan	2004
Topotecan-induced bronchiolitis. Southern medical journal, 2004, Volume: 97, Issue:7 Topics: Antineoplastic Agents; Bronchiolitis; Carcinoma; Enzyme Inhibitors; Female; Humans; Middle Aged; Peritoneal Neoplasms; Topoisomerase I Inhibitors; Topotecan	2004
Comparison of efficacy and toxicity profile between intraperitoneal and intravenous topotecan in human ovarian cancer xenografts. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2006, Feb-18, Volume: 38, Issue:1 Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Omentum; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan; Xenograft Model Antitumor Assays	2006
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecologic oncology, 2006, Volume: 103, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Retrospective Studies; Topotecan	2006
Papillary serous carcinoma of peritoneum: presentation of 2 cases. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:10 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Postoperative Care; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Topotecan; Treatment Outcome	2006
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC cancer, 2007, Apr-15, Volume: 7 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins	2007
Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topotecan	2008
Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecologic oncology, 2001, Volume: 83, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topotecan	2001